CiVi Biopharma
Wade Benton joined CiVi Biopharma in May 2018 as vice president of clinical development. Wade has more than 20 years of experience in clinical research in the pharmaceutical industry, most recently as the chief executive officer and chairman of Eicos Sciences, a wholly-owned subsidiary of CiVi Biopharma.
Wade has successfully led medical and clinical teams in pulmonary arterial hypertension, chronic kidney disease and heart failure at Actelion and Relypsa.
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.